Number of pages: 100 | Report Format: PDF | Published date: March 06, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
Report Attribute |
Details |
Market Size Value in 2022 |
US$ 260 million |
Revenue Forecast in 2031 |
US$ 424.56 million |
CAGR |
5.6% |
Base Year For Estimation |
2022 |
Forecast Period |
2023-2031 |
Historical Year |
2021 |
Segments Covered |
Technology, Age Group, Sector Type, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global sickle cell disease diagnostics market was valued at US$ 260 million in 2022 and is expected to register a revenue CAGR of 5.6% to reach US$ 424.56 million by 2031.
Sickle Cell Disease Diagnostics Market Fundamentals
Sickle cell disease is a genetic disorder affecting hemoglobin, a protein in red blood cells that carries oxygen throughout the body. People with sickle cell disease have abnormal hemoglobin that can cause red blood cells to become malformed and break down prematurely, leading to various complications. Sickle cell disease is caused by HBB gene mutations, which provide instructions for making beta-globin, a hemoglobin subunit. Sickle cell disease diagnostics refers to the various methods and tests used to diagnose and confirm the presence of sickle cell disease in individuals. Sickle cell disease diagnostics can include newborn screening, hemoglobin electrophoresis, hemoglobin solubility tests, genetic testing, and physical exams. Early diagnosis of sickle cell disease is important to manage its complications and prevent serious health problems.
The sickle cell disease diagnostics market is expected to show positive growth during the coming years due to the increasing prevalence of sickle cell disease, advancements in diagnostic technologies, growing awareness of the disease, and increasing healthcare expenditure. Moreover, a rise in the development of new diagnostic technologies, such as genetic testing, HPLC, and point-of-care diagnostic devices, which provide accurate and efficient testing options, especially in regions with limited healthcare facilities, is propelling revenue growth in the global market. Early diagnosis and treatment of a disease can prevent complications and improve quality of life. Implementing newborn screening programs in many countries is also expected to drive the revenue growth of the sickle cell disease diagnostics market.
North America is expected to dominate the market due to the high prevalence of sickle cell disease and the availability of advanced diagnostic technologies. The market in Asia Pacific is also expected to register significant revenue growth during the forecast period due to the increasing awareness of the disease and the development of advanced healthcare infrastructure in the region.
However, the market revenue growth may be hindered by the high cost of diagnostic tests, limited access to healthcare facilities, and lack of awareness about sickle cell disease in some communities from different regions.
[5675675]
Sickle Cell Disease Diagnostics Market Dynamics
The increasing prevalence of sickle cell disease globally is prominently driving the revenue growth of the market. Sickle cell disease is the most common health disorder in individuals of African descent. However, it also occurs in people of Hispanic, Middle Eastern, and Mediterranean ancestry. According to the WHO, around 5% of the world’s population carries trait genes for hemoglobin disorders. The percentage of hemoglobin disorders is up to 25% in some regions. Around 300,000 babies are born with these diseases each year globally. The development of new diagnostic technologies, such as genetic testing, point-of-care testing, and high-performance liquid chromatography (HPLC), has improved the accuracy and efficiency of sickle cell disease diagnostics, propelling the growth of the sickle cell disease diagnostics market.
Governments in many countries are taking steps to improve the diagnosis and treatment of sickle cell disease. For instance, the Centers for Disease Control and Prevention (CDC) has launched the Sickle Cell Data Collection program, which collects health information about people with sickle cell disease to study long-term trends in diagnosis, treatment, and healthcare access with sickle cell disease in the United States. Additionally, patient advocacy groups, healthcare organizations, and governments are taking initiatives to increase awareness of sickle cell disease, driving the demand for sickle cell disease diagnostics. The implementation of newborn screening programs in many countries has led to early diagnosis and treatment of sickle cell disease, which is significantly fueling the sickle cell disease diagnostics market. Moreover, the major companies are investing in developing and innovating existing and new diagnosing techniques for sickle cell disease diagnostics, which is also expected to boost the market growth.
However, the lack of awareness in developing countries and the high cost of treatment after diagnosis restrict the revenue growth of the global sickle cell disease diagnostics market. Moreover, the lack of awareness about the latest diagnostic tools and techniques among healthcare professionals in developing countries is impeding the development of the sickle cell disease diagnostics market. Developing and obtaining regulatory approval for diagnostic tools can be lengthy and expensive, slowing the introduction process of new products into the market.
Sickle Cell Disease Diagnostics Market Ecosystem
The global sickle cell disease diagnostics market is analyzed from four perspectives: technology, age group, sector type, and region.
Sickle Cell Disease Diagnostics Market by Technology
[756456]
Based on the technology, the global sickle cell disease diagnostics market is segmented into hemoglobin electrophoresis, point-of-care tests, high-performance liquid chromatography (HPLC), and others.
The hemoglobin electrophoresis segment dominated the sickle cell disease diagnostics market with the largest revenue share in 2022. The hemoglobin electrophoresis segment is further sub-segmented into isoelectric focusing and others. Hemoglobin electrophoresis is the gold standard for diagnosing sickle cell disease. It has been used for decades and has a high level of accuracy in detecting and identifying different types of hemoglobin in the blood based on their electrical charge, allowing for the detection of abnormal hemoglobin associated with sickle cell disease and boosting segmental growth. The test is widely available, relatively inexpensive, and easy to perform with minimal technical expertise, which makes it accessible to healthcare providers in various settings. Moreover, hemoglobin electrophoresis also provides valuable information about the type and severity of sickle cell disease, which can help healthcare providers determine appropriate treatment options, thus propelling the demand for hemoglobin electrophoresis.
The point-of-care tests segment is expected to be the fastest-growing segment during the forecast period. Point-of-care tests are convenient and can be performed outside of a traditional laboratory setting, allowing for quicker and easier diagnosis of sickle cell disease in remote or underserved areas. This is especially important in regions with limited access to diagnostic testing and healthcare services. Point-of-care tests are rapid and provide results within minutes, allowing immediate diagnosis and treatment. This can significantly improve patient outcomes and reduce the burden of sickle cell disease on healthcare systems. Advancements in technology have led to the development of more accurate and reliable point-of-care tests for sickle cell disease, making them an increasingly attractive option for healthcare providers. These tests are becoming more affordable and accessible, further driving growth in the point-of-care tests segment.
Sickle Cell Disease Diagnostics Market by Age Group
Based on the age group, the global sickle cell disease diagnostics market is segmented into newborn screening (12 months and below), adult screening (25 to 60 years), and other age groups.
The newborn screening segment accounted for a significant revenue share of the sickle cell disease diagnostics market in 2022. Newborn screening is a mandatory public health program in many countries to identify and treat newborns with certain genetic conditions, including sickle cell disease. This has led to a high testing volume, making it the largest segment. Early detection of sickle cell disease through newborn screening can lead to better health outcomes for affected individuals. Prompt identification of sickle cell disease allows for early interventions and treatments to prevent serious complications and improve quality of life, boosting segment revenue growth.
Sickle Cell Disease Diagnostics Market by Laboratory Type
Based on the laboratory type, the global sickle cell disease diagnostics market is segmented into government labs, private labs, and others.
The government labs segment accounted for the largest revenue share of the sickle cell disease diagnostics market in 2022. Government labs provide healthcare services to a large portion of the population, particularly in developing countries with limited access to private healthcare facilities. As a result, government labs have a high volume of sickle cell disease diagnostic testing, making it the largest segment in the sickle cell disease diagnostics market. Furthermore, government labs typically have access to funding from the government or other public sources, allowing them to invest in advanced diagnostic technologies and equipment. Government labs often have the mandate to provide affordable healthcare services to the public, which makes them an attractive option for sickle cell disease diagnostic testing, as it can be expensive in private healthcare facilities, thus fueling the revenue growth in this segment. Additionally, government labs are often responsible for implementing public health programs, including newborn screening programs for sickle cell disease, which can further drive growth in this segment.
Sickle Cell Disease Diagnostics Market by Region
Geographically, the global sickle cell disease diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market in North America accounted for a significant market revenue share in 2022. The rising prevalence of sickle cell disease in North America is boosting the demand for early diagnosis of sickle cell disease diagnostics in the region. According to CDC, approximately 100,000 people in the United States are affected by sickle cell disease. This disease is detected in about 1 of every 365 African American births. North America has a well-established and advanced healthcare infrastructure that supports the development and adoption of innovative diagnostic technologies. This infrastructure enables the region to attract significant investments in sickle cell disease diagnostics. The governments in North America have implemented several initiatives to promote the diagnosis and treatment of sickle cell disease, including public health programs and funding for research and development. These initiatives have increased awareness of sickle cell disease and its impact, boosting regional growth. Advances in diagnostic technologies have made it possible to detect sickle cell disease earlier and more accurately. This has led to an increase in demand for sickle cell disease diagnostic tests in North America. Personalized medicine, which involves tailoring medical treatment to the individual characteristics of each patient, is gaining popularity in North America. Diagnostic tests for sickle cell disease are essential to personalized medicine, driving demand for such tests in the region.
Sickle Cell Disease Diagnostics Market Competitive Landscape
The prominent players operating in the global sickle cell disease diagnostics market are:
Sickle Cell Disease Diagnostics Market Strategic Developments
The prominent players operating in the global sickle cell disease diagnostics market are Streck, Inc., BioMedomics, Inc., Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, and Bio-Rad Laboratories Inc.
The global sickle cell disease diagnostics market was valued at US$ 260 million in 2022.
The hemoglobin electrophoresis segment dominates the global sickle cell disease diagnostics market.
Geographically, North America accounts for the largest market revenue share, followed by Europe. Asia Pacific is the fastest-growing regional market for sickle cell disease diagnostics.
Limited awareness among healthcare professionals, lack of effective treatment options, and regulatory challenges are some restricting factors of the sickle cell disease diagnostics market growth.
*Insights on financial performance are subject to the availability of information in the public domain